News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Elsevier launches Complete Anatomy female model, the most advanced full female anatomy model available in the world

Elsevier

The innovative 3D solution marks a major milestone in education equality with the representation of the full female anatomy in the study of the human body The launch is coming at a time when females are more likely to be misdiagnosed for health conditions compared to male counterparts Elsevier, a global leader in research publishing and information analytics, is pleased to announce the launch of the most advanced 3D full female model ever available, as part of the latest addition to its 3D platform, Complete Anatomy. This marks the first time that a female model has been built with this level of detail in its entirety, to represent the female — versus replacing specific areas of the male anatomy with female features. The solution allows educators to visualize, edit and teach anatomy entirely from the female perspective for the first time, all in stunningly realistic 3D detail. Complete Anatomy is a revolutionary cloud-based medical education platform from 3D4 Medical by Elsevier and is the No. 1 top-selling medical category app on iPad in the U.S., with over 20 million downloads globally. The launch signifies a major milestone in equal representation by preparing medical, nursing and allied health students with the most complete understanding of the female anatomy. Historically, the full female anatomy has been underrepresented in the study of the human body. Now, educators can choose the sex with which they’d like to teach their full curriculum, in addition to having the option of switching between male and female anatomies to teach comparative differences in sex-specific regions of the body. The Complete Anatomy female model provides educators with a more comprehensive teaching approach that allows them to switch seamlessly between teaching both female and male anatomy. Elizabeth Munn, Managing Director, Global Medical Education, Elsevier, said: “As an advocate for content that is diverse and inclusive, we are thrilled to offer this groundbreaking full female model to allow educators to teach anatomy in an equal and comprehensive way. Complete Anatomy is continuing Elsevier’s rich heritage of innovation in education by delivering on our vision of providing transformative medical education solutions. We are proud to take this step forward in addressing gender bias and believe Complete Anatomy’s female model will have a tremendous impact on the educational experience of medical students worldwide as well as on the outcomes of patients they treat in the future.” Informed by four years of expert research and development, anthropological data from specialist texts, academic papers and customer feedback, the addition of the female model to Complete Anatomy’s 3D platform provides an unprecedented opportunity to study the female form in more detail than before. Complete Anatomy’s female model will benefit all courses that teach anatomy and is an essential virtual tool for learners studying outside the lab who need a deeper understanding of both male and female anatomies. The Complete Anatomy female model includes: The full skeletal system — A complete female skeletal system includes a wide array of unique features, rarely seen in anatomical texts. Sexual differences have been applied to areas such as the pelvis and skull. Long bones have been proportioned, and bone angles accurately reflect the uniquely female architectural skeletal base. Accurate portrayal of muscles — To create an accurate representation of the female anatomy, the overall volume of muscle mass for each muscle has been reduced by roughly 30%, in line with research findings from the broadest demographic of females as compared to males. Visually detailed female-specific regions — The female-specific regions have been created in detail that is equivalent to the male counterpart. Breast tissue can be hemisected or quartered to reveal the underlying tissues with a more accurate distribution and representative state of the mammary glands, now shown as nonlactating, unlike most anatomical resources. The reproductive organs from the internal and external genitalia have been remodeled to accurately show their continued relationship. Comparative functionality — Users can switch between models for comparative study on any part of the male and female forms, compare sexual differences and reveal the origin and distribution of nerves. Users can learn continuity from a “Gray’s Anatomy”-inspired atlas and dissection course, take quizzes and watch videos to test their skills. Lead subject matter expert on the update Yasmin Carter, PhD, Assistant Professor of Translational Anatomy at the UMass Chan Medical School, Worcester, MA, USA said: “One of the inherent dangers in using only the male body as ‘anatomical normal’ and the female body as a variation, is perpetuating sexist attitudes. This unconscious bias will be carried by learners into their future interactions with the body, including potentially with patients. Complete Anatomy is creating a platform of representation that is diverse, balanced, and most importantly, accurate. By giving educators the option to choose the female body as the basis for their students’ education, Elsevier is helping evolve equitable teaching practices by normalizing the female body. Complete Anatomy’s female model will support me in training the next generation of medical professionals to be more appropriate and inclusive.” Elsevier has been working continuously to enhance its global portfolio of medical education solutions, digital learning tools and analytics for medical and nursing students to prepare them for successful careers in health professions. Recently, Elsevier announced the acquisition of Osmosis, a visual learning platform for medical students and professionals, which followed other acquisitions in nursing and health education, including Shadow Health, a developer of virtual nursing simulations, and the 2019 acquisition of 3D4 Medical, the creator of the Complete Anatomy app. In addition, Elsevier launched ClinicalKey Student, an interactive medical education platform equipped with learning tools to support both students and faculty. --- About Complete Anatomy Complete Anatomy from 3D4 Medical by Elsevier is the world's most advanced 3D anatomy platform. The revolutionary cloud-based education platform allows users to investigate the minute detail of the human anatomy in incredible 3D. Complete Anatomy is transforming medical learning and practice across the world, leading the way in the production of groundbreaking 3D medical technology. Featuring over 2.5 million registered customers and over 20 million downloads globally, Complete Anatomy is used daily in over 350 top universities around the world as well as with global clinical organizations. Complete Anatomy’s award-winning software has been featured on stage at Apple and Microsoft events, was honored as the Winner of the Apple Design Awards in 2016, and is the No. 1 top-selling medical category app on iPad in the U.S. 3D4 Medical has been developing medical and anatomical products since 2009 and was acquired by Elsevier in 2019. 3D4 Medical by Elsevier has continued to provide industry-leading innovations that have allowed new ways for students, educators and those in the medical community to learn and understand the human anatomy. To learn more about Complete Anatomy’s female model and the experience it provides users, please visit the 3D4 website. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Teresa Mueller, Vice President, Global Health Markets Elsevier Communications t.mueller@elsevier.com Contact Details Elsevier Communications Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/

January 10, 2022 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

McDade Products, LLC Joins Forces with G Medical Tests and Services to Provide U.S. Retailers with Millions of COVID-19 at-Home PCR Test Kits

G Medical Innovations Holdings

FDA EUA-approved PCR collection kit tests provide 24-hour certified lab results and retail for $9.99 In response to a national shortage of COVID-19 test options, Pittsburgh-based McDade Products, LLC has partnered with G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), to manufacture several million U.S. FDA Emergency Use Authorization (EUA) approved COVID-19 PCR collection test kits available for retailers for sale by the end of January, 2022. McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry. McDade Products is now accepting orders for the co-branded LiveNow PCR Collection Kit, which will retail for $9.99. The diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19. Users register with the lab online, collect a nasal swab sample at home, and send the sample to G Medical’s CLIA-certified lab with the pre-paid return pack. On average, tests results are expected to be available online within 24 hours from the time the sample is received. G Medical’s labs are approved by the FDA under the EUA. Currently, G Medical has two CLIA-certified labs; one in Southern California, and the other in North Carolina. In addition, G Medical has launched six testing centers in California, with many more planned. G Medical’s labs are capable of being run 24 hours per day 7 days a week, and can each process up to 24,000 COVID tests per hour to meet the current demand. The first test kit order is for 4 million units. G Medical will be selling these units wholesale for $3.25 each, reflecting gross profit of $7 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. According to Grand View Research (grandviewresearch.com) the global PCR and real time PCR molecular diagnostics market was valued at over USD $23.6 Billion in 2020 and expected to expand at a CAGR (compound annual growth rate) of 0.9% between 2021 and 2028. “For decades, we’ve been committed to empowering clinicians and patients to better manage their health outcomes. By partnering with McDade Products, we can make our SARS-CoV2 certified lab testing accessible and convenient for customers and retailers nationwide. With new cases abound, and the world grappling with PCR test shortages there is a tremendous opportunity to provide safety, and relief to the world economy with a significant financial benefit to our shareholders,” said Dr. Yacov Geva, President and CEO of G Medical Innovations. “As a trusted and established next-generation mobile health and e-health company that provides clinical and consumer medical-grade health monitoring solutions, G Medical Innovations enables us to offer our retail customers with an end-to-end solution to address the national shortage of reliable COVID-19 diagnostic tests,” said Michael McDade, CEO of McDade Products, LLC. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders, plans to open Covid-19 testing centers in California, timing of the delivery of tests results, anticipated gross profits, financial benefit to shareholders, and addressing the national shortage of reliable COVID-19 diagnostic tests. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com McDade Products, LLC Jennifer Faines 412-559-2860 Jennifer.faines@gmail.com Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 10, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company

Amorphical

Amorphical’s Novel COVID-19 Oral and Inhaled Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Outstanding preliminary results were revealed in an interim analysis of an on-going Phase II clinical study in Israel for treating patients with moderate-to-severe COVID-19. AMOR-18, a new drug consisting of Amorphical’s unique amorphous calcium carbonate (ACC), was the active pharmaceutical ingredient. The preliminary analysis focused onAMOR-18’s capability of stopping the currently-acute pandemic urgencies from further harming hospitalized patients. Out of a total of 37 patients recruited in one of the study centers, none of the 18 patients taking the drug was transferred to an intensive care unit (ICU) and all were released within a few days from the hospital. In a sharp contrast, 32% of the 19 participants in the placebo group, were transferred to ICU and 10% died. Thus far, sixty-six (66) patients were treated, six (6) in Phase I, fifty-eight (58) in Phase II and two (2) in a compassionate care program. The interim analysis is performed in one of the 4 participating medical centers (Ziv Medical Center) in which 37 moderate-to-severe patients had participated in a randomized, placebo controlled, double-blind study.19 patients were treated with placebo, and 18 patients with AMOR-18. Last week, Amorphical announced that all 18 patients with COVID-19, hospitalized with moderate or severe symptoms, who had received the drug AMOR-18, have recovered and were discharged within a few days. None of the patients treated with the drug were transferred to the intensive care unit or died. By contrast, among the nineteen (19) individuals in the placebo arm, six (6) were transferred to intensive care, and two of them died.As a part of Amorphical’s compassionate care program, two other patients with gravely serious conditions were given the drug outside the study in the same hospital. Both have recovered and were discharged from the hospital. “Since none of the patients receiving the drug (AMOR-18) were transferred to intensive care or died, this interim outcome is a tremendous success for our patients and community”, said Dr. Nashat Abu Saleh, Co-Director of the Coronavirus Department at the Ziv Medical Center in Safed, Israel, where this phase II clinical trial was conducted. Positive Interim Results The ongoing Phase II study (AMCS-COVID-001) is a Prospective, Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, and Efficacy of ACC(named AMOR-18 ), taken daily sublingually and via inhalation administration, concomitantly with Best Available Care (BAT), compared to placebo and BAT. The first efficacy measure assesses the rate of change from baseline to study completion (hospital release or death), as defined by an improvement of 1 or more points on an ordinal 8-point scale. The second measure of efficacy is the ratio of mortality to Intensive Care Unit (ICU) admissions. The preliminary analysis was conducted on a total of 37 patients, equally randomized to treatment with either AMOR-18 (ACC) or a placebo, concomitantly with BAT. Six (6) out of the group of 19 patients (32%) treated with placebo concomitantly with BAT were transferred to the ICU, two of whom died (33%). Conversely, none of the hospitalized patients actively treated with ACC) were transferred to the ICU or died. Dr. Kamal Abu-Jabal, Co-Director of the Outpatient Hospital Unit and ICU COVID-19 Unit at Ziv Medical Center, said: "I believe this treatment has the potential to significantly reduce the mortality rate in patients with moderate-to-severe COVID-19 symptoms and has a broader potential for treating patients who contract similar viral infections. We found safety, effectiveness, and no side effects. Together with the treatment available today for COVID-19, Amor 18 may turn this pandemic to an illness from which one can recover relatively easily, even severely ill hospitalized patients. In our opinion, we are at a turning point of a fundamental change in dealing with COVID-19". Yossi Ben, Founder & CEO of Amorphical, noted: "The interim results bring a great deal of interest among countries and the scientific community. Amorphical is currently conducting several negotiations for such international participation in efforts to combat the pandemic. We intend to provide preferred distribution channels to countries who will support further clinical studies, as well as assist in obtaining regulatory related activities of the drug treatment". The Study at Glance Initially, 6 patients (not included in the reported 37) were recruited for a Training/Safety Study (Phase I) at 3 research hospital sites in Israel. This stage assessed the safety and administration protocol of AMOR- 18 in combined sublingual and inhalable modes. This part of the study concluded that it was safe to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study. The study was originally designed to include 100 patients in total with one-on-one randomization (active + BAT vs. placebo + BAT), and conducting the Phase II study at four medical centers in Israel: Shamir, Ziv, Kaplan, and Mayanei Hayeshua. However, in December 2021, Amorphical conducted an interim analysis of the study on all 37 participating patients in one of the study institutions – Ziv Medical Center. The principal investigators at this Center are Dr. Kamal Abu-Jabal, and Dr. Nashat Abu-Saleh. The interim analysis was conducted due to the vast global spread of COVID-19, a temporary lack of patient candidates in Israel, and anurgent needfor opening study centers outside of Israel. The interim analysis was performed by an independent statistician. The Phase II study in Israel will continue to recruit the intended 100 patients at all the specified hospitals, potentially also including the Wolfson Medical Center-Israel. Preliminary Analysis The study population included 37 patients who tested positive for COVID-19 according to a PCR test and were hospitalized due to the severity of their conditions. After screening, 18 patients were randomly assigned to active treatment group and 19 to a placebo group. The ICU and mortality rate analysis was assessed, along with 95% Wilson Score Confidence Intervals (CI), comparing the study arms with a Cochran-Mantel-Haenszel Test. The Intent to Treat (ITT) analysis set consists of all subjects being randomized. In accordance with the ITT principle, subjects are kept/remain in their originally assigned treatment group. For subjects randomized for treatment by either ACC or placebo, the rate of ICU admittance or death occurred only in the placebo group, and was not observed in the treatment group (p<0.01).All patients in the ACC group tolerated the treatment well, were released from the hospital, and did not report any treatment-related adverse side effects. Further analysis of the interim resultsis on going. According to the preliminary analysis, subjects randomly placed in the active arm (ACC) had a statistically and significantly lower risk of death or ICU admission compared to those randomized into the placebo arm. In the active arm, 0.0% (0/18, 95% CI: [0.00%;17.59%]) of the subjects died or were transferred to the ICU, vs. 31.6% (6/19, 95% CI: 15.36%;53.99%]) in the placebo arm. This difference was highly significant, (p<0.02). The early analysis of the interim results concludes that treating moderate-to-severe COVID-19 hospitalized subjects with ACC AMOR-18is effective in reducing the risk of worsening of the disease. In addition to the goals outlined above, Amorphical has established a compassionate use program, which has treated two additional patients with very severe COVID-19 infection and significant comorbidities. Although these patients did not meet our study inclusion criteria, both responded well to the ACC treatment and were released home. Amorphical plans to complete phase II and immediately proceed to phase III. Phase III will further evaluate the effectiveness of ACC and confirm its safety, tolerability, and efficacy on a global scale. It will then be internationally submitted for prompt regulatory approvals with the intention to support the worldwide efforts against the current and similar future pandemics. Amorphical is currently engaged in approval process with ANVISA (the Brazilian Health Regulatory Agency) to begin recruitment for a similar study with 100 additional patients at 7 hospital sites in Brazil. About the ACC (AMOR-18) Therapeutic Mechanism ACC consists of nanometric and amorphous primary particles, and has much higher solubility & bioavailability than crystalline calcium carbonate (CCC). Amorphical successfully manufactures and markets several dietary supplements based on ACC, which help build, maintain, and restore the body’s health and strength. Preclinical and early clinical studies reveal that ACC provides unique therapeutic and biomedical activities for treating diseases and conditions, associated with acidosis conditionsby directly targeting specific organs or systems. There is a growing body of scientific literature indicating the effects of low pH (metabolic acidosisinside and around organs and cells) on: (a) the progression of SARS-type viruses in general, and COVID-19 in particular; (b) the detrimental impact of excessive acidity on lung inflammation and functions; and (c) the exaggerated immune response (expressed as a cytokine storm), leading to devastating lethal outcomes. In our current study, ACC aims to serve as a pH modulator of the extracellular compartment, inhibiting the virus cell’s penetration, and replication within body cells, and regulating abnormal immune responses. These therapeutic activities are enabled by ACC’s unique amorphous and nanometric state, combined with its carbonate component. These assumed therapeutic activities inspired the current clinical study for treating the entire range of patients suffering from mild-to-severe COVID-19 infection. About Amorphical Amorphical is an Israeli pioneering biotech company, established to develop health and therapeutic products based on amorphous calcium carbonate (ACC). Amorphical has succeeded in synthesizing, stabilizing, and preserving a naturally rare form of calcium carbonate used by nature’s most sophisticated “calcium-producing machine” – the blue crayfish. The synthesis and formulations have been scaled into a manufacturing GMP (Good Manufacturing Practices) operation for supplements in the Arava Desert in Israel. We develop novel solutions for numerous major diseases, based on the uniquely bioactive, nanometric and amorphous ACC. The company has applied for over 130 patent applications in over 40 countries, with over 60 patents already granted worldwide. ( www.amorphical.com )) Contact Details Amorphical Amorphical management info@amorphical.com Company Website https://www.amorphical.com/contact-us/

January 06, 2022 02:00 PM Eastern Standard Time

Image
Article thumbnail News Release

Michael Edwards CEO MedMinder Announcement

MedMinder

MedMinder Systems Inc. (“MedMinder”), the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution, today announced that Michael F. Edwards has been appointed as Chief Executive Officer. “I am delighted to welcome Mike as our new Chief Executive Officer,” said David Shulkin M.D., Chairman of the Board of Directors of MedMinder. “The COVID-19 Pandemic has highlighted the critical importance of access to medications and remote care. MedMinder is purpose built to assist polychronic patients improve medication adherence and simplify digital care solutions. Mike brings the right set of skills and experience to build upon MedMinder’s platform and take the organization to the next level. Finally, I would like to thank Eran Shavelsky, the founder of MedMinder who led the company from inception into becoming a leading provider of online pharmacy and connected care solutions. Eran’s vision and persistence made MedMinder what it is today.” “I am so proud of the MedMinder team for building such a valuable digital health solution which helps so many people,” said Eran Shavelsky, MedMinder Founder. “I am confident that under Mike’s leadership the company will further grow and expand.” Mike has a passion for helping solve some of the biggest problems in healthcare. As a veteran healthcare executive Mike has built and led high performing organizations within pharmacy, technology and consumer engagement. Prior to joining MedMinder, Mike was Chief Commercial Officer at Truveris. Mike held various executive roles at Optum, a subsidiary of United Health Group (NYSE:UNH). Most recently Mike was President, Commercial Markets at OptumRx. Prior to that role, Mike was part of the executive team at Catamaran where he was instrumental in executing the integration with Optum. Mike held leadership positions at Vitals, Express Scripts and Medco, where he began his healthcare career. Mike holds a bachelor’s degree from Rutgers University and a Masters degree from NJIT in International Business Finance as well as an MBA in the Management of Technology. Mr. Edwards commented: “I’m impressed by MedMinder’s unique ability to engage customers, deliver measurable health outcomes, and simplify the inherent complexity associated with pharmacy care. I look forward to being part of a team with a restless ambition to improve patient experiences and unlock the potential of combining pharmaceutical and digital care.” ABOUT MEDMINDER MedMinder is the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients. Founded in 2007 by Eran Shavlelsky, MedMinder currently employs over 150 team members between its Massachusetts and New York locations and is recognized as an ultra-high-growth digital healthcare company. MedMinder’s touch screen-enabled, automatic pill dispenser is the first device on the market capable of delivering medications from its pharmacy directly to patients’ doors in pre-organized daily trays for the entire month. With a customer-first approach, MedMinder is continually innovating to improve and meet the evolving needs of patients, caregivers, practitioners and payors. More information can be found at https://www.medminder.pharmacy. Contact Details MedMinder Systems Inc. Ethan Davis +1 339-777-4662 ethan.davis@medminder.com Company Website https://www.medminder.pharmacy

January 05, 2022 12:00 PM Eastern Standard Time

Article thumbnail News Release

Cortland Biomedical Announces New Product Development Team Appointments to Support Continued Growth

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, today announced the appointment of three new hires to its New Project Development team. Robert Demaree has been appointed as a Senior Process Engineer. He brings 25 years of experience in various technical roles throughout his career with experience in development of fiber optic cable processes, printed circuit board materials, and electrical generators. He also served as a subject matter expert in composite materials and management of the chemistry group at IMR Test Labs. Rob holds a bachelor’s degree in Mechanical Engineering and a master’s degree in Materials Science and Engineering from Virginia Polytechnic Institute. Tony Maslowski joins the team as a Senior Project Manager to oversee new product development programs and drive projects toward timely completion. He brings more than 30 years of experience in various technical and project management roles throughout his career. He has worked in the chemical and medical device industries, notably with companies such as DePuy and Aesculap. Tony holds a bachelor’s degree in Ceramic Science and Engineering from Penn State and an MBA from Temple University. Additionally, Tony is co-owner of two US patents and holds several certifications in project management. Zach Robbins has been hired as a Textile Process Engineer to help develop processes related to knit and woven fabric product development projects. Zach comes to Cortland with four years of experience in the textile industry, most recently working with finishing and dyeing of knitted products at Gehring Tricot. He holds a bachelor’s degree in Materials Science Engineering – Polymers, Textiles and Fibers from Georgia Tech. Cortland Biomedical’s team nearly doubled in size during the 2021 calendar year, with a particular focus on engineering hires to support its robust new product pipeline. The company is looking to fill additional positions across engineering, manufacturing and administrative support. “We’re proud to be growing in the Cortland Community and continuing to add topnotch talent to further our mission of adding maximum value and innovation to meet our customers’ needs for custom biomedical textile solutions fabricated for their specific medical device applications,” said Eric Brown, Director of Operations, Cortland Biomedical. “We welcome Robert, Tony and Zach to the team and look forward to seeing their contributions to new product development in the year ahead.” In 2021, Cortland completed the transition to its state-of-the-art facility, which construction began on in 2018. Cortland’s ISO 13485:2016 -certified facility on Lime Hollow Rd. has 20,000 sq.ft. of cleanroom manufacturing space, with Class 7 and Class 8 cleanrooms third party-certified to ISO14644. It also features a qualified ASTM Type 1-B water system with sustained monitoring. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 05, 2022 10:05 AM Eastern Standard Time

Article thumbnail News Release

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Quidel Corporation

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories. Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance. Titled “The Diversity of Bartonellosis Manifestations and Challenges to Treatment,” the webinar is conducted by Monica E. Embers, Ph.D.,* associate professor of microbiology and immunology and director of vector-borne disease research at Tulane National Primate Research Center in Covington, Louisiana. Her research at Tulane focuses on the effectiveness of antibiotics and other therapeutics to eradicate Borrelia burgdorferi from the body while also exploring the many avenues related to persistent Lyme disease. Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act. Appointed to this position by the U.S. Department of Health and Human Services, the Working Group serves as a federal advisory committee to provide expertise and recommendations regarding all tick-borne diseases, evaluate tick-borne disease research priorities and help ensure coordination between federal agencies. The primary function of the Working Group is the development of a report of findings and recommendations regarding the federal response to tick-borne disease prevention, treatment and research, which it submits to Congress and the Secretary of Health and Human Services. On the webinar, Dr. Embers describes the possible clinical presentations (signs and symptoms) of Bartonellosis; compares Bartonellosis to Lyme borreliosis in terms of detection, persistence and treatment; and identifies research efforts needed to better diagnose and cure Bartonellosis. The timing and relevance for the webinar is particularly important as Lyme disease is on the rise to record numbers throughout the country and potentially affected as many as 476,000 citizens in 2021. Among those invited to view the webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations and others interested in the subject. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. *Dr. Embers receives an honorarium for conducting the webinar sponsored by Quidel. Contact Details breakwhitelight JAMES YEAGER +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

January 05, 2022 06:00 AM Pacific Standard Time

Article thumbnail News Release

AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Appyea

AppYea (OTC: APYP), a medical device technology company, announced today the deemed completion of its previously announced acquisiiton of SleepX, an innovative medical device company focused on the development of SleepX’s flagship product DreamIT – an uncompetitively accurate wearable monitoring solution to treat sleep apnea and snoring and fundamentally improve quality of life. After the acquisiiton, SleepX will continue operating under its own brand name as a fully owned AppYea subsidiary. The merged company will focus on further development and commercialization of SleepX’s solution, including continued R&D investments and new initiatives in sales and marketing. Also, SleepX intends to begin a calibration trial with DreamIT. “I am delighted that we have completed the acquisition of SleepX. The company develops a wearble technology solution to treat snoring and sleep apnea, which is patent protected in the US, EU and Israel, and caters to two growing markets in high demand", said Boris (Bary) Molchadsky, AppYea’s Chairman. “This aqisition allows us to execute our growth strategy towards the beginning of DreamIT’s marketing during the second half of 2022, while continuing its development with the Biomedical Department at Ben Gurion University in Israel, and launching our first calibaration trial. Meanwhile, we are examining the acquisition of other synergetic activities that will complement the SleepX vision to improve sleep quality and quality of life globally.” According to the market intelligence company Fior Markets, the global anti-snoring treatment market is expected to grow at a 9.07% CAGR to USD 8.6 billion by 2028. The global sleep apnea devices market is expected to grow at a 6.2% CAGR to USD 6.1 billion by 2028, according to Grand View Research’s report. About SleepX SleepX, an AppYea (OTC: APYP) subsidiary, is a medical device company, focused on the development of uncompetitively accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life. The company’s solutions are based on its proprietary IP portfolio of AI and sensing technologies for the tracking, analysis, and diagnosis of vital signs and other physical parameters during sleep time, offering extreme accuracy and resistance at affordable cost. SleepX’s flagship solution is DreamIT – a patented wristband communicating with its smartphone app to gently vibrate with every breathing interruption, and cause a shift from deep to lighter sleep, training the brain to breath properly. The app tracks sleep patterns and using the company’s machine learning technology to adapt the treatment and recommend improvements according to the user’s sleep and breathing patterns. In addition to reducing snoring and improving sleep quality, users will be able to access important statistics relating to their sleep patterns via the app to track and detect anomalies over time. DreamIT is being developed in collaboration with the Biomedical department of the Ben Gurion University of the Negev and is patent protected in the US, EU and Israel. According to the market intelligence company Fior Markets, the Global Anti-Snoring Treatment Market is expected to grow to USD 8.6 billion by 2028, at a 9.07% CAGR during 2021-2028. The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a 6.2% CAGR from 2021 to 2028, reaching USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc SleepX was founded in 2019, and following the acquisition, its headquarters are in Boca Raton, Florida. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop amd market our products, our ability to maange the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

December 31, 2021 08:45 AM Eastern Standard Time

Video Image
Article thumbnail News Release

Inaugural VinFuture Prize Award Ceremony – Celebrating 4 Scientific Innovations for Humanity

Vingroup

HANOI, VIETNAM - Media OutReach - 20 December 2021 - One year after its launch, the VinFuture Prize Council has completed the evaluation process and selected 4 groundbreaking scientific innovations that have made and will continue to make positive impacts in the everyday lives of millions of people around the world. Prize winners will be announced at the inaugural VinFuture Prize Award Ceremony to be held on January 20, 2022 at the Hanoi Opera House and the VinFuture Sci-tech Week during January 18-21, 2022 in Hanoi. This is an international event to honor outstanding scientific achievements and promote innovations for humanity in 2021 with the participation of world-leading scientists, policy makers, leaders of technology corporations, and the Prize winners. The award ceremony will be held on January 20, 2022 evening to honor the winners of the inaugural VinFuture Prize, including the VinFuture Grand Prize and 03 Special Prizes for female innovators, innovators from the developing countries, and innovators with outstanding achievements in emerging fields. As part of the Award Ceremony event series, VinFuture will organize a sci-tech week for the scientific community, business and start-up leaders in industry and technology. The Foundation will also hold dialogues and interactive sessions with the Prize Council members and the VinFuture Laureates which will catalyze the intellectual connection between Vietnam's scientific and technological community and the world as well as bridge academia and industry, thus contributing to the transformation of science and technology innovations into real life applications. Commenting on the upcoming events, Professor Sir Richard Henry Friend – Chair of the VinFuture Prize Council and a 2010 Laureate of the Millennium Prize, said: " Science and technology need to deliver benefits to all peoples and all nations. The VinFuture Prize will recognize those whose brilliant science or engineering achievements can have positive impact on the lives of millions of people across the planet." The VinFuture Foundation is founded by Mr. Pham Nhat Vuong - Chairman of Vingroup, and his wife - Mrs. Pham Thu Huong, with the vision of creating meaningful change in the everyday lives of millions of people. In its inaugural year, VinFuture received 599 quality nominations from more than 60 countries around the world. Among these, nearly 100 nominations came from the world's top 2% most-cited scientists, many of whom are laureates of distinguished awards, such as the Nobel Prize, Breakthrough Prize, Tang Prize, Japan Prize, among others. All the nominations were assessed in multiple evaluation and selection rounds by a 12 member- Pre-screening Committee, and then by 11 members of the Prize Council. With a large number of quality nominations going through a rigorous assessment process conducted by the Prize Council of globally influential scientists and leaders in academia, research, and innovation, the 2021 VinFuture Prize is expected to identify breakthrough inventions and innovations that will bring about practical applications and meaningful impacts on the everyday lives of people. Remarkably, the in-person presence of great minds of the global science and technology community at the inaugural VinFuture Prize Award Ceremony and the VinFuture Sci-tech Week will contribute to positioning Vietnam as a new destination full of potentials and open up opportunities to build direct and multi-dimensional cooperative relationships between scientists and entrepreneurs, promoting the commercialization and application of scientific innovations into the real world. Besides the Laureate Announcement and the Award Ceremony on January 20th, 2022, there will be academic activities taking place from January 18-21, 2022, which include: - Conversation with the VinFuture Prize Council members - Symposium: Science for Life - Scientific Dialogue with the inaugural VinFuture Prize Laureates. The VinFuture Prize Foundation, introduced on International Solidarity Day, December 20 th, 2020, is an independent and non-profit organization in Vietnam. The Foundation was established with the vision of catalyzing meaningful change in the everyday lives of millions of people by honoring transformational technological innovations at a global scale. The Foundation's core activity is awarding the annual VinFuture Prize for breakthrough scientific and technological innovations that have made or have the potential to create meaningful changes in people's lives. In addition, the Foundation will conduct many activities to accomplish its mission, such as funding research projects, collaborating in academic development, and promoting STEMM education. A total of four prizes are awarded by the VinFuture Prize Foundation every year, consisting of the VinFuture Grand Prize valued at US$3 million - one of the largest ever annual prizes globally. VinFuture also awards 03 Special Prizes, each valued at US$500,000, dedicated to female innovators, developing country innovators, and innovators with outstanding achievements in emerging fields. Contact Details Vingroup Media Contact v.nammh@vingroup.net

December 20, 2021 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

Record 40,000 Transplants Honors Legacy of Donors

United Network for Organ Sharing

Today, Dec. 17, 2021, the United States has officially surpassed 40,000 transplants in one year, a historic first for the nation. This is according to United Network for Organ Sharing (UNOS), the engine that powers the national organ donation and transplantation system under contract with the federal government. 2020 marked the 10th consecutive record-breaking year for organ donations from deceased donors and the 8th in a row for deceased donor transplants. “Reaching 40,000 organs transplants in a single year is a testament to the lifesaving work being done day in and day out that makes our donation and transplantation system the highest performing in the world,” said Matthew Cooper, M.D., president of the UNOS Board of Directors. "It is also a testament to the generosity of so many inspiring donors and their courageous families who gave the gift of life. “This news serves as a reminder that no matter what challenges we face as a nation, our community of doctors, patients, donor families, hospitals, organ procurement professionals, and advocates are dedicated to building on past successes to save even more lives. But there is always more work to do.” As of today, 106,962 men, women and children are on the waiting list for a transplant, which is at the lowest it has been since 2009. The list topped 124,000 at its height in 2014. "Every one of us has the potential to save multiple lives by registering to be an organ, tissue and eye donor," Cooper said. Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Matthew Cooper, M.D., FACS, is president of the UNOS Board of Directors, Director of Kidney and Pancreas Transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital, and a professor in the department of surgery at Georgetown University School of Medicine. ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Eric Steigleder +1 804-782-4730 eric.steigleder@unos.org Company Website https://unos.org

December 17, 2021 06:43 PM Eastern Standard Time

Image
1 ... 162163164165166 ... 210